GlassScriptPhysician profile
Vignan Manne
NPI 1346660420
$5,031.45
in general payments reported to CMS, 2019-2025
19 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $136 · 2021: $388 · 2022: $411 · 2024: $1,534 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804 · Education: $53.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.24 |
| Education | $53.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.85 | 2021-2025 | |
| Boston Scientific Corporation | $700.84 | 2019-2025 | General - Therapies, Exalt Model D, Endovive Low Profile Replacement Button |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $448.57 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $446.57 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $343.26 | 2024 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $244.14 | 2020-2025 | Entyvio, Eohilia |
| Glaxosmithkline, LLC. | $217.15 | 2025 | |
| Sequana Medical US INC. | $178.39 | 2025 | Alfapump System |
| Gilead Sciences, INC. | $153.30 | 2019 | |
| Pfizer INC. | $147.95 | 2022-2025 | |
| Mirum Pharmaceuticals, INC. | $142.31 | 2025 | Livmarli |
| Genentech USA, INC. | $125.00 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $98.45 | 2025 | |
| Lilly USA, LLC | $87.53 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $80.21 | 2025 | Rebyota |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $78.54 | 2024 | Interstim |
| Qol Medical, LLC | $36.22 | 2024 | Sucraid |
| Aimmune Therapeutics, INC. | $23.14 | 2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $21.03 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vignan Manne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.